Profound Medical Corp. (PRN.TO) Research

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Market snapshot

Symbol
PRN.TO
Price
$9.60
Day change
-0.41%
Market cap
$205.1M
P/E ratio
-5.47x
52-week range
5.23-12.4
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 1 month

Peer companies

  • CareRx Corporation (CRRX.TO)
  • Cybin Inc. (CYBN.NE)
  • Medical Facilities Corporation (DR.TO)
  • Eupraxia Pharmaceuticals Inc. (EPRX.TO)
  • HLS Therapeutics Inc. (HLS.TO)
  • Jushi Holdings Inc. (JUSH.CN)
  • NervGen Pharma Corp. (NGEN.V)
  • Quipt Home Medical Corp. (QIPT.TO)

Open Profound Medical Corp. (PRN.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.